| 英文别名 |
Olmesartan Medoxomil Related Compound A;6,6-dimethyl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]furo[3,4-d]imidazol-4-one;Olmesartan Lactone I;Olmesartan Lactone Impurity;3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-6,6-dimethyl-2-propyl-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one;1-{[2′-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1H-furo[3,4-d]imidazol-6(4H)-one;3,6-Dihydro-6,6-dimethyl-2-propyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-4H-furo[3,4-d]imidazol-4-one;Olmesartan Medoxomil EP Impurity B;Olmesartan Medoxomil EP Impurity B, RNH-6352;3,6-Dihydro-6,6-dimethyl-2-propyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-4H-furo[3,4-d]imidazol-4-one (ACI);4H-Furo[3,4-d]imidazol-4-one, 3,6-dihydro-6,6-dimethyl-2-propyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- (9CI);Olmesartan medoxomil impurity B [EP];OLMESARTAN MEDOXOMIL IMPURITY B [EP IMPURITY];CML390S782;CS-0131985;1ST182294;OLMESARTAN MEDOXOMIL IMPURITY B;DTXCID20156457;UNII-CML390S782;DTXSID90233966;DA-56429;4H-Furo(3,4-d)imidazol-4-one, 3,6-dihydro-6,6-dimethyl-2-propyl-3-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-;849206-43-5;OLMESARTAN MEDOXOMIL IMPURITY B (EP IMPURITY);AKOS040758378;Olmesartan lactone;OlmesartanLactoneImpurity;1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1h-furo[3,4-d]imidazol-6(4h)-one;6,6-Dimethyl-2-propyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-3,6-dihydro-4H-furo(3,4-d)imidazol-4-one;HY-131276;6,6-Dimethyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-one;Q27275537 |
在线客服
专业包装 品类齐全
厂家直发 快捷到货
品牌正品 质量保证
自助下单 尝选无忧
